Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04432857 · ClinicalTrials.gov registry record · Phase 1
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
A Phase 1 study of Cervical Cancer and Triple Negative Breast Cancer, sponsored by Adlai Nortye Biopharma Co..
- Active
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
- 6
- Study locations
NCT04432857: Active Phase 1 study of Cervical Cancer and Triple Negative Breast Cancer, sponsored by Adlai Nortye Biopharma Co..
NCT04432857 is a Phase 1 study of Cervical Cancer and Triple Negative Breast Cancer that is active but no longer recruiting, run by Adlai Nortye Biopharma Co.. The registered enrollment target is 63 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (89% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04432857, a Phase 1 study of Cervical Cancer and Triple Negative Breast Cancer, is active but no longer recruiting, sponsored by Adlai Nortye Biopharma Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open-label, multicenter, phase Ib study to evaluate the safety and preliminary efficacy of AN0025 in combination with pembrolizumab in patients with locally advanced/metastatic tumors. It will include a dose-limiting toxicity observation phase followed by an expansion phase. All enrolled patients will be treated with AN0025 and Pembrolizumab until the patient experiences disease progression, unacceptable toxicity or withdraws consent, or for a maximum of 35 cycles (approximately 2 years). The dose of pembrolizumab will remain constant at 200 mg every 3 weeks (Q3W) for each dose level of AN0025 and in each cohort.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG AN0025
Study Locations (6)
Other
- Centre Léon Bérard - Lyon
- Gustave Roussy - Paris
Missouri
- Washington University School of Medicine - Siteman Cancer Center - St Louis
Texas
- MD Anderson Cancer Center - Houston
Utah
- University of Utah School of Medicine Huntsman Cancer Institute - Salt Lake City
Virginia
- University of Virginia - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2020-08-20 |
| Est. Completion | 2025-01-30 |
| Phase | Phase 1 |
What the registry record for NCT04432857 still lists
NCT04432857 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (89% lower).
The record links to 5 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04432857 lists 6 locations in 5 states (Other, Missouri, Texas).
Frequently Asked Questions
What is clinical trial NCT04432857 about?
NCT04432857 is a clinical study titled "AN0025 and Pembrolizumab Combination in Advanced Solid Tumors". This is an open-label, multicenter, phase Ib study to evaluate the safety and preliminary efficacy of AN0025 in combination with pembrolizumab in patients with locally advanced/metastatic tumors. It will include a dose-limiting toxicity observation phase followed by an expansion phase. All enrolled ...
What is the current status of trial NCT04432857?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2020-08-20. Estimated completion is 2025-01-30.
What conditions does trial NCT04432857 study?
This clinical trial studies the following conditions: Cervical Cancer, Triple Negative Breast Cancer, Urothelial Carcinoma of the Bladder, Microsatellite Stable (MSS) Colorectal Cancer (CRC), NSCLC, Squamous or Non-Squamous.
What interventions are being tested in trial NCT04432857?
The interventions under investigation include: Pembrolizumab (DRUG), AN0025 (DRUG).
Who is sponsoring clinical trial NCT04432857?
This trial is sponsored by Adlai Nortye Biopharma Co., which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04432857 being conducted?
This trial has 6 study locations across Missouri, Texas, Utah, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04432857's enrollment target sits among peer trials
63 87th of 144 higher than 58 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
-
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI